Friday, May 20, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Association between natural immunity and risk of SARS-CoV-2 reinfection and COVID-19 hospitalization

by Medical Finance
in Coronavirus
Study: Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Image Credit: joshimerbin/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Against the background of the ongoing coronavirus disease 2019 (COVID-19) pandemic, with high vaccine coverage in several regions coupled with increasing rates of new infections in some hotspots, a new Swedish study examines the protective effect of immunity engendered by natural infection in contrast to hybrid immunity.

Study: Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Image Credit: joshimerbin/Shutterstock
Study: Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Image Credit: joshimerbin/Shutterstock

Introduction

There has been much controversy over whether individuals who have a history of prior COVID-19 need to be vaccinated against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Such individuals generally show an immune response to the administration of a COVID-19 vaccine, indicating that vaccination continues to be beneficial.

However, pending hard evidence, the task of persuading those with prior infection to take a primary series of the vaccine, plus boosters, is made more difficult. With vaccine passports becoming a requirement in some places, considerable differences have been revealed in the approach to issuing such passports. Should those with prior infection be recognized as immune or only those with hybrid immunity?

The current study, which appears in The Lancet Infectious Diseases, aimed to shed light on this issue.

What did the study show?

The study used Swedish national registers maintained by three different entities to form three cohorts. The first comprised unvaccinated people with natural immunity, and unvaccinated infection-naïve individuals, of the same sex and age. The second and third cohorts included those who had taken one or two doses of the vaccine after a prior infection, again matched by age and sex to those with prior infection but unvaccinated.

The investigators looked for evidence of SARS-CoV-2 infection and hospitalization for COVID-19 over a period from March 20th, 2020, until October 4th, 2021, and September 5th, 2021, respectively. However, follow-up was shorter in cohorts 2 and 3, which were enrolled later, and during a period of lower infections.

Over the follow-up period of 164 days, non-immune individuals had over 99,000 documented infections, with approximately 2,000 hospitalizations. Conversely, those with natural immunity developed 34,000 infections, with approximately 3,200 hospitalizations. The risk of infection after natural infection was 95% lower. In comparison, the risk of hospitalization in this group was initially higher for the first three months but was reduced by 87% over the next 20 months.

The risk was higher among the older age groups and those born out of Sweden as well as those with higher education.

During a follow-up of 52 days, after a single dose of vaccine, following prior infection, the risk was reduced by 58% for reinfection, compared to those with natural immunity alone, in cohort 2. The effect weakened thereafter. It was also weaker in older people and those who had other illnesses.

There were eight hospitalizations in the one-dose hybrid immunity group, vs. 110 in the natural immunity group, for a reduction of 44%.

After two doses in previously infected individuals, there were just over 400 reinfections, with six hospitalizations, compared to 800 cases and 40 hospitalizations in those with natural immunity alone.

Two-dose hybrid immunity reduced reinfection risk by 56% compared to natural immunity, lasting at least nine months. The number of people with natural immunity who need to take two doses of vaccine in order to prevent one reinfection is 767.

What are the implications?

Overall, in those with prior infection, both one and two doses of vaccine were associated with a reduced risk of either reinfection or hospitalization than natural immunity alone. In the natural immunity cohort, the risk of reinfection was low for the next 20 months or more but reduced further with vaccination for the next nine months.

It is important to note that the difference in the number of cases and of hospitalizations in the natural immunity and hybrid immunity cohort is small, especially in the latter. Thus, there remains little evidence to promote the need for vaccination in those previously infected, especially with the long duration of immunity in this study, for 20 months or more.

Natural immunity seems to be of longer duration than vaccine-induced immunity, corroborating an Israeli study that recently published early findings and an earlier study by the same authors who showed waning vaccine effectiveness in Sweden within a few months. Nonetheless, hybrid immunity showed better protection against hospitalization than natural immunity, but the small numbers in this scenario call for further studies.

These findings suggest that if passports are used for societal restrictions, they should acknowledge either a previous infection or vaccination as proof of immunity, as opposed to vaccination only.”

This is of special relevance in regions that have been poorly covered by vaccination, especially since the current Omicron variant possesses impressive vaccine-antibody escape characteristics.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant. Image Credit: creativeneko/Shutterstock

Effectiveness of prior infection in preventing reinfection with Omicron and other SARS-CoV-2 variants in Qatar

by Medical Finance
May 19, 2022
0

In a recent study published on the medRxiv* preprint server, researchers estimate the effectiveness of prior infection in preventing reinfection (PEs)...

Study: Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinology. Image Credit: Design_Cells/Shutterstock

Study investigates incident diabetes burden and risk in post-acute COVID-19 patients

by Medical Finance
May 19, 2022
0

In a recent study published in The Lancet Diabetes and Endocrinology, researchers examined the post-acute risk and burden of incident...

Study: Adherence of SARS-CoV-2 delta variant to surgical mask and N95 respirators. Image Credit: Maridav/Shutterstock

Efficacy of surgical masks and N95 respirators in lowering SARS-CoV-2 transmission

by Medical Finance
May 19, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers determined the adherence of severe acute respiratory syndrome coronavirus 2...

Study: Genetic and Immunological Characterization of Commercial Infectious Bronchitis Virus (IBV) Vaccines Used in Korea. Image Credit: Rawpixel.com/Shutterstock

Researchers characterize vaccines for infectious bronchitis virus

by Medical Finance
May 19, 2022
0

A recent study posted to the Research Square* server characterized the genetic and immunological aspects of the infectious bronchitis virus...

Study: Regulatory T-cells are central hubs for age-, sex- and severity-associated cellular networks during COVID-19. Image Credit: People Image Studio/Shutterstock

Mapping regulatory T-cell populations in COVID-19 patients

by Medical Finance
May 19, 2022
0

In a recent study published on the medRxiv* preprint server, researchers used mass spectrometry to investigate changes to immune systems,...

Study: Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity. Image Credit: Imilian/Shutterstock

SARS-CoV-2 viral mutations shown to have a limited effect on T cell immunity

by Medical Finance
May 19, 2022
0

In a recent study published in the journal of Science Translational Medicine, researchers examined neutralizing antibody and T cell responses...

Next Post
Study: A virus-specific monocyte inflammatory phenotype is induced by SARS-CoV-2 at the immune–epithelial interface. Image Credit: MIA Studio/Shutterstock

Researchers investigate SARS-CoV-2 specific inflammatory response

IVM-MS2, “The most compact all-in-one IntraVital two-photon microscopy system in the world”

IVM-MS2, “The most compact all-in-one IntraVital two-photon microscopy system in the world”

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Pregnancy 620x480
    Scientists shed light on placenta’s role in transferring vitamin D to fetus during pregnancy
  • Study: Post-acute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Image Credit: creativeneko / Shutterstock
    Long COVID is characterized SARS-CoV-2 antigen persistence in the gut mucosa
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply